Compare Teradyne, Inc. (TER) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teradyne, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Teradyne, Inc. trades at $407.54 (market cap $64.38B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Teradyne, Inc. pays a 0.13% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Teradyne, Inc. for 37 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TER | VRTX | |
|---|---|---|
Market Cap | $64.38B | $128.16B |
Volume | 2,394,954 | 806,603 |
Sector | Technology | Health |
52-Week High | $483.84 | $557.96 |
52-Week Low | $132.05 | $407.37 |
Typical Hold Time | 37 Days | 120 Days |
Enterprise Value | $64.12B | $122.29B |
Dividend Yield | 0.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Teradyne (TER) trades at $398.72, down 7.34% over 24 hours, but maintains strong technical support near $399. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and expanding AI-driven test portfolio through new products like Magnum E2 and Iris 100. Revenue growth is projected to accelerate from $3.19B in 2025 to $4.5B in 2026, with net income margin improving to 25.76%.
Outlook remains positive with 61% analyst buy ratings and $461.50 consensus price target, representing 16% upside. Key risks include semiconductor cycle volatility and competitive pressure from KLAC & COHU. Institutional accumulation continues with recent purchases by Envestnet and Nykredit, supporting bullish sentiment despite insider selling.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
